Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
1. GSK's Q1 sales grew by 2% year-over-year, reaching $9.46 billion. 2. Vaccine sales declined 8%, driven by lower demand for Arexvy and Shingrix. 3. Specialty medicines reported double-digit sales growth, mainly in HIV and oncology. 4. GSK reaffirmed 2025 guidance, expecting 3-5% sales growth. 5. Stock price rose 3.57% to $40.37 during premarket session.